Piedmont Participating in Large Global Trial Investigating Ventilation, ECMO Use on COVID-19 Patients

Jul 20, 2020 | ARDS, Coronavirus, COVID-19, ECMO, News, Piedmont Healthcare, Ventilation

Piedmont Participating in Large Global Trial Investigating Ventilation, ECMO Use on COVID-19 Patients

Piedmont Healthcare is participating in a large international clinical trial to study the effects of ventilation and Extracorporeal Membrane Oxygenation, or ECMO, in the critical care setting on patients suffering from the combination of COVID-19 and Acute Respiratory Distress Syndrome (ARDS). ECMO is a medical device used to support patients whose heart and lungs require additional assistance to function, similar to putting a patient on bypass during open-heart surgery.

The Study

The trial is based out of Piedmont Atlanta Hospital, where the local primary investigators are Peter Barrett, M.D., director of Piedmont’s ECMO program and medical director of the Cardiac Critical Care Units, and David Dean, M.D., surgical director for heart transplant and mechanical circulatory support. The study began in Australia and has come to encompass more than 300 sites in nearly 50 countries. In the United States, 200 participants will be enrolled in the study, which began on March 1. The study is scheduled to be completed by December 31. To be eligible for the study, patients must have a confirmed or suspected COVID-19 infection with ARDS and require ECMO.

“The pulmonary/critical care and cardiovascular groups at Piedmont have been on the forefront of providing innovative treatments for COVID-19 patients throughout the pandemic,” Dr. Barrett said. “We are hopeful that the data we are collecting as part of this study will help to improve protocols for COVID-19 patients across the country and will help to improve their clinical outcomes.”

The primary outcome measure of the study is in-hospital mortality. Secondary measures include:

· Death on ECMO

· Stroke

· Bloodstream infection

· Lung complications requiring surgical treatment

· Blood transfusion

· Acute kidney injury

· Length of ICU stay

· Death after hospital discharge

Piedmont has found high survival rates for its COVID-19 patients on ECMO, with 18 of 22 recovering.

About Piedmont Heart

Piedmont Heart Institute ranks in the top 5 percent in the country among cardiovascular organizations and is the only program in Atlanta consistently recognized with the Cardiac Care Excellence Award from Healthgrades—a mark of quality it has earned for more than ten years. Piedmont is an international leader in cardiovascular research, enabling patient access to innovative therapies not available elsewhere.

Lead Research/Investigator

Peter Barrett, M.D., director of Piedmont’s ECMO program and medical director of the Cardiac Critical Care Units

David Dean, M.D., surgical director for heart transplant and mechanical circulatory support.

0 Comments

Pin It on Pinterest